New inhaler BGF 160 studied for COPD breathing issues

NCT ID NCT06110403

Recruiting now Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing an inhaler called BGF 160 (also known as Breztri Aerosphere) in 35 adults with stable COPD. The goal is to see how the medicine changes the complexity and variability of breathing patterns over 30 days. Participants will use the inhaler twice daily, and researchers will measure lung function and breathing mechanics. This is an early-phase, open-label study to understand how the drug works, not to prove it cures COPD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGF 160 (budesonide, glycopyrrolate, formoterol fumarate) as an inhaler
What this could lead to: If successful, this could show how BGF 160 improves breathing patterns in COPD, supporting its use for symptom control.
What could go wrong: This is a small, early-phase study (35 people) with no placebo group, so results may not be conclusive or apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

CHU de Lille
RECRUITING

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.